Endocrine Abstracts

Background: The most common type of thyroid cancer is the well-differentiated thyroid carcinoma (DTC) and that includes papillary (PTC) and follicular carcinoma (FTC). The PTC would represent 50–90% and the FTC over 15–30%. Within the PTC, the most frequent is the classical variant (over 80%), followed by follicular variant (10%) and the rest of variants (<10%). Furthermore, there are differences between PTC and FTC in age at diagnosis, local extension, multicent...

Objectives: Verify the efficacy of the GLP-1 analogue exenatide in patients with type 2 DM assisted in our hospital area.Material and methods: This study included patients who initiated this therapy in 2008 and 2009. Through 3 months were analyzed the outcomes of weight, HbA1c and the development of adverse effects.Results: The process included 32 patients, 21 men and 11 women, with ages between 26 and 73 years old (mean age 48.78 ...

RET is a tyrosine kinase receptor activated by GDNF, NTN, ART and PSPN through GFRa1,2, 3 and 4 respectively. Activation of the receptor elicits intracellular pathways such us Ras/MAPK and PI3K/AKT leading to differentiation and proliferation. Our group has previously shown that RET is expressed specifically in the somatotroph cell population within the pituitary gland, both in rats and in humans. We have also shown that, in absence of its ligand GDNF, RET induces activation o...

We previously described a significant response to RTX treatment in patients with active TAO, with no effect on TRAb and hyperthyroidism. In order to study the effect of RTX in the orbit, we analyzed the orbital tissues of 9 patients with TAO at decompression after RTX (n.2) or other treatments. Decompression was carried out in 2 patients for sight threatening optic neuropathy and in 7 for correction of proptosis. Of the RTX treated patients, one was decompressed after 12 month...

BRAFV600E is the most common mutation in papillary thyroid carcinoma (PTC). Anatomo-patology and clinical features of PTC with BRAFV600E are well described in literature.Aim of this study was to examine the prognostic significance of BRAFV600E in patients with PTC and a follow-up of 15-20 years.Genomic DNA was purified from 67 paraffin-embedded tumoral tissue. A PCR-SSCP analysis of exon 15 of BRAF ...

Undifferentiated thyroid carcinoma is a highly aggressive human cancer with poor prognosis. A strong association has been observed between undifferentiated thyroid carcinoma and TP53 mutations. Plitidepsin (AplidinTM) a novel anticancer compound from a sea tunicate, has been reported to induce apoptosis independently of TP53 status. We investigated the actions of plitidepsin in human thyroid cancer cells. initiallyexperiments using primary cultured cells from a d...

Introduction: Waist circumference is a validated tool to measure obesity-associated cardiovascular risk factor. However it does not differentiate between superficial and visceral abdominal fat. Ultrasonography has many advantages over TC/DEXA in abdominal fat assessment, specially imaging pre-peritoneal, omental and retroperitoneal fat. Our aims were to validate the diagnostic technique and to observe correlations between different abdominal fat layers with clinical and analyt...

Undifferentiated/Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and deadly cancers. It is characterized by loss of thyroid expression markers and no response to conventional treatments. ATC incidence is low representing <2% of all thyroid carcinomas. This, together with its high mortality, makes difficult the development of clinical trials. In our previous works, we have developed a system to culture patient-derived thyroid cancer cells (h7H) that is a go...

Introduction and objectives: The treatment with monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) is a new group of drugs that allows us to reach the therapeutic targets of low density cholesterol (LDL-c) in patients intolerant to statins or those who despite treatment with maximum doses of them do not obtain a proper lipid control.Material and methods: We performed a descriptive observational study. We include all ...

Introduction: PCSK9 inhibitors (iPCSK9) have previously been evaluated through controlled clinical trials showing up to 60% reduction in LDL cholesterol concentrations. However, we still do not have enough data regarding the real life experience of the treatment.Objectives: 1) Describe patients with hypercholesterolemia treated with iPCSK9 in clinical practice.2) Evaluate treatment efficacy and safety.Methods...